Navigation Links
Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
Date:1/9/2008

SEATTLE, Jan. 9 /PRNewswire/ -- Omeros Corporation announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Omeros. Deutsche Bank Securities Inc. will be acting as the sole book-running manager. Pacific Growth Equities, LLC will be acting as the co- lead manager, and Leerink Swan LLC and Needham & Company, LLC will be acting as co-managers. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus may be obtained from Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telephone at (800)-503-4611 or by email: prospectusrequest@list.db.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urol
'/>"/>

Copyright©2008 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2

Related biology technology :

1. Genelex Corporation Defends Consumers Right to Obtain DNA Information:
2. Pharmos Corporation Completes Initial Closing of Private Placement
3. Pharmos Corporation Announces Board and Management Changes
4. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
7. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
10. FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
11. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... Scientists at the Center for Learning and ... the California -based biopharmaceutical company Magceutics, ... for reversing memory decline in mice with Alzheimer,s Disease. ... improvement in advanced stage AD mice. The study is ... decline for advanced stage AD mice, and is also ...
(Date:5/16/2013)... Canada (PRWEB) May 16, 2013 On ... and costs over one billion dollars. Despite this investment, ... With stakes this high, is your clinical trial design ... deliver the best outcomes? , Dr. Frederic Sax, Global ... will discuss the use of data, information and technology ...
(Date:5/16/2013)... 16, 2013 Reportlinker.com announces ... is available in its catalogue: ... for Acute Coronary Syndromes - APAC ... http://www.reportlinker.com/p01182969/MediPoint-Diagnostic-Cardiac-Biomarkers-for-Acute-Coronary-Syndromes---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic MediPoint: ... Syndromes - APAC Analysis and Market ...
(Date:5/16/2013)... ON (PRWEB) May 16, 2013 DNA Genotek, ... announced ‘Spit for Africa’, a sponsorship program in conjunction with ... is designed to improve access and reduce the cost of ... projects such as the Human Heredity and Health in Africa ... the AfSHG. , The aim of the AfSHG ...
Breaking Biology Technology:Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 3MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 5MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 6MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 7MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 8DNA Genotek Inc. Announces Spit for Africa Program 2DNA Genotek Inc. Announces Spit for Africa Program 3
... Application in the ... European Union, ... Food and Drug Administration (FDA) has approved the design of,a single, ... with chemotherapy as first-line,treatment in patients with non-small cell lung cancer ...
... the aim of a new licensing deal between the ... and the company, based in West Sacramento, Calif., have ... of jointly-owned intellectual property stemming from inventions both on ... enable manufacture of very thin, very small wires, films ...
... 16 Roche (OTCQX:,RHHBY; SWX: ROG.VX; RO.S), a world-leading ... has extended its,offer to acquire all of the outstanding ... ) to 5:00 p.m., New York City time on ... to expire at 5:00,p.m., New York City time, on ...
Cached Biology Technology:Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 2Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 4Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 5Solar energy technology licensed 2Roche Extends Tender Offer for Ventana 2Roche Extends Tender Offer for Ventana 3Roche Extends Tender Offer for Ventana 4Roche Extends Tender Offer for Ventana 5
(Date:5/16/2013)... at sites outside the bone marrow in the ... in Munich now show that a specific type of ... cells. , Balanced hematopoiesis is essential for the function ... place mainly in the liver and the spleen. Later ... this tissue normally serves as the sole source of ...
(Date:5/16/2013)... Enang Abwe, a conservationist working in Cameroon and the ... has just been awarded the prestigious Whitley award. ... often called "The Green Oscars" because it celebrates the ... working in developing countries. Abwe was selected for ... and preserve Cameroon,s Ebo Forest and its wildlife inhabitants., ...
(Date:5/16/2013)... Germany , May 16, 2013 ... Value Enhancement Award on Tuesday to Germany,s ... its exceptional biometric border control system. DERMALOG ... with the Best Practices Award in the category Global ... its cutting edge Biometric   Border Control System ...
Breaking Biology News(10 mins):Herpes infections: Natural killer cells activate hematopoiesis 2Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Global Biometrics and Border Control Award for DERMALOG 2Global Biometrics and Border Control Award for DERMALOG 3Global Biometrics and Border Control Award for DERMALOG 4
... (highly active anti-retroviral therapy) has emerged as an extremely ... however, HAART can never truly eradicate the virus as ... chemical called suberoylanilide hydroxamic acid (SAHA), recently approved as ... on, latent HIV, making it an attractive candidate to ...
... MARCH 16, 2009--Throughout the world, nitrogen compounds are ... combustion of fossil fuels. These pollutants are deposited ... many hundreds of miles downwind of their release ... are a case in pointthough they contain little ...
... Researchers at the Johns Hopkins Bloomberg School of ... broiler poultry operations may contribute to the dispersion ... for human exposure to drug-resistant bacteria. The findings ... production and exposures to antibiotic resistant pathogens. Previous ...
Cached Biology News:Tree species composition influences nitrogen loss from forests 2Flies may spread drug-resistant bacteria from poultry operations 2
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Acrylamide PAGE 40% Solution, 1 l. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
Recombinant Mouse IL-23, CF...
Biology Products: